References
- Arrighi HM, Metter EJ, Guess HA, Fozzard JL, Natural history of benign prostatic hyperplasia and risk of prostatectomy, Urology 1991; 38(1 Suppl): 4-8 https://doi.org/10.1016/0090-4295(91)80191-9
- Korea National Statistical Office, Korean Census 2005. Daejeon: Korea National Statistical Office [cited 2008 Oct 11], Available from: URL: http://www.kosis.kr
- Lee E, Park MS, Shin C, Lee H, Yoo K, Kim Y, et al. A high risk group for prostatism: A population-based epidemiological study in Korea, Br J Urol 1997; 79(5):736-741 https://doi.org/10.1046/j.1464-410X.1997.00149.x
- Stoevelaar HJ, McDonnell J, Changing therapeutic regimens in benign prostatic hyperplasia, Pharmacoeconomics 2001;19(2):131-153 https://doi.org/10.2165/00019053-200119020-00003
- Han KS, Hong SJ, Chung BH, Changing trends in the management of benign prostatic hyperplasia during recent 5 years, Korean J Urol 2005; 46(5):458-462
- AUA Practice Guidelines Committee, Guideline on the management of benign prostatic hyperplasia, J Urol 2003; 170(2 Pt 1): 530-547 https://doi.org/10.1097/01.ju.0000078083.38675.79
- Djavan B, Chapple C, Milani S, Marberger M, State of the art on the efficacy and tolerability of the alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia, J Urol 2004; 64(6): 1081-1088 https://doi.org/10.1016/j.urology.2004.07.031
- Maclure M. Why me? versus why now? - differences between operational hypothesis in case control versus case-crossover studies, Pharmacoepidemiol Drug Saf 2007;16(8):850-853 https://doi.org/10.1002/pds.1438
- Chrischilles E, Rubenstein L, Chao J, Kreder KJ, Gilden D, Shah H. Initiation of nonselective alpha1 antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: A retrospective cohort study, Clin Ther 2001;23(5):727-743 https://doi.org/10.1016/S0149-2918(01)80022-9
- Souverein PC, Van Staa TP, Egberts AC, De la Rosette JJ, Cooper C, Leufkens HG. Use of alpha blockers and the risk of hip/femur fractures, J Intern Med 2003; 254(6): 548-554 https://doi.org/10.1111/j.1365-2796.2003.01227.x
- McMahon AD, Evans JM, McGilchrist MM, McDevitt DG, MacDonald TM, Drug exposure risk windows and unexposed comparator groups for cohort studies in pharmacoepidemiology, Pharmacoepidemiol Drug Saf 1998;7(4): 275-280 https://doi.org/10.1002/(SICI)1099-1557(199807/08)7:4<275::AID-PDS363>3.0.CO;2-N
- Maclure M. The case-crossover design: A method for studying transient effects on the risk of acute events, Am J Epidemiol 1991; 133(2):144-153 https://doi.org/10.1093/oxfordjournals.aje.a115853
- McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al, The long-term effect of doxazosin, finasteride,and combination therapy on the clinical progression of benign prostatic hyperplasia, N Engl J Med 2003; 349(25):2387-2398 https://doi.org/10.1056/NEJMoa030656
- Hartikainen S, Lonnroos E, Louhivuori K. Medication as a risk factor for falls: Critical systematic review, J Gerontol A Biol Sci Med Sci 2007; 62(10): 1172-1181 https://doi.org/10.1093/gerona/62.10.1172
- Macdonald R, Wilt TJ, Howe RW. Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: A systematic review of efficacy and adverse effects, BJU Int 2004; 94(9): 1263-1270 https://doi.org/10.1111/j.1464-410X.2004.05154.x
- Milani S, Djavan B. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on a1-adrenoceptor antagonists. BJU Int 2005; 95 Suppl 4:29-36 https://doi.org/10.1111/j.1464-410X.2005.05485.x
- Hall GC, McMahon AD, Comparative study of modified release alpha blocker exposure in elderly patients with fractures, Pharmacoepidemiol Drug Saf 2007; 16(8):901-907 https://doi.org/10.1002/pds.1402
Cited by
- HPMC의 점도에 따른 염산 알푸조신 과립정제의 용출률 조절 vol.34, pp.3, 2009, https://doi.org/10.7317/pk.2010.34.3.269
- アジアのデータベースとレコード・リンケージ vol.16, pp.1, 2009, https://doi.org/10.3820/jjpe.16.27
- Risk of fractures associated with treatment for benign prostate hyperplasia in men vol.22, pp.2, 2009, https://doi.org/10.1007/s00198-010-1320-4
- Alpha-adrenergic blocker mediated osteoblastic stem cell differentiation vol.416, pp.3, 2011, https://doi.org/10.1016/j.bbrc.2011.09.095